Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
November 11, 2025
Endocrinology Today—November 11, 2025
November 11, 2025
Obesity Today—November 11, 2025
November 11, 2025
Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery
November 10, 2025
Oncology Video Recap—November 10, 2025
November 10, 2025
Hematology Today—November 10, 2025
November 10, 2025
Oncology Today—November 10, 2025
November 10, 2025
AI in Healthcare and Digital Health Today—November 10, 2025
November 9, 2025
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding
November 8, 2025
Lucid Diligence Brief: Lumonus A$25M Series B
November 7, 2025
AHA 2025 Preview: Key Cardiovascular Highlights to Watch
November 7, 2025